T1	Outcomes 396 410	bleeding rates
T2	Outcomes 1188 1228	including adherence to prasugrel therapy
T3	Outcomes 1336 1342	Â± 3).
T4	Outcomes 1343 1378	Major, minor, and minimal bleedings
T5	Outcomes 1474 1483	patients.
T6	Outcomes 1484 1516	Low residual platelet reactivity
T7	Outcomes 1641 1660	event was epistaxis
T8	Outcomes 1728 1754	because of bleeding events
T9	Outcomes 1764 1785	possible side effects
T10	Outcomes 1791 1860	2), or medical decisions not associated with bleeding or side effects
T11	Outcomes 1888 1919	(4.7%) temporarily discontinued
T12	Outcomes 1991 2028	definite or probable stent thrombosis
T13	Outcomes 2059 2121	develop de novo myocardial infarction and 1 an ischemic stroke
T14	Outcomes 2129 2194	were 11 deaths because of heart failure or refractory cardiogenic
T15	Outcomes 2201 2225	in 9, pulmonary embolism
T16	Outcomes 2229 2242	1, and cancer
T17	Outcomes 2276 2316	practice, major and minor bleeding event
T18	Outcomes 2415 2422	trials.
T19	Outcomes 2423 2449	The minimal bleeding event
